Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies

British Journal of Dermatology

Volumn 157, Issue SUPPL. 2, 2007, Pages 52-55

  Schofer H ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Genital warts; HPV; Imidazoquinolines; Imiquimod; Topical immunomodulators

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOKINE; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; INTERFERON; PEGINTERFERON; PODOPHYLLOTOXIN;

ANUS; ARTICLE; BURNING SENSATION; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; COST MINIMIZATION ANALYSIS; CREAM; DEPRESSION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ERYTHEMA; FLU LIKE SYNDROME; GENITAL SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; INFLAMMATION; LONG TERM CARE; MONOTHERAPY; OINTMENT; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; SKIN INDURATION; SKIN MANIFESTATION; SKIN ULCER; TAMPON; TOPICAL TREATMENT; TREATMENT DURATION; VERRUCA VULGARIS; VIRUS REPLICATION;

AMINOQUINOLINES; ANUS DISEASES; CONDYLOMATA ACUMINATA; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HUMANS; INTERFERON INDUCERS; MALE; TREATMENT OUTCOME;

EID: 36549063366     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08274.x     Document Type: Article

References (25)

1. Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis 2001 1:3.
2. Christophers E, Rigel D (eds). The therapeutic potential of immune response modifiers in dermatology. Br J Dermatol 2003 149 (Suppl. 66 1 70.
3. Hengge UR, Cusini M. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br J Dermatol 2003:149 (Suppl. 66 15 9.
4. Schofer H, Van Ophoven A, Henke U et al. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur J Dermatol 2006 16:642 8.
5. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006 16:83 97.
6. Rockley PF, Tyring SK. Interferons alpha, beta and gamma therapy of anogenital human papillomavirus infections. Pharmacol Ther 1995 65:265 87.
7. Brockmeyer NH, Poffhoff A, Bader A et al. Treatment of condylomata acuminata with pegylated interferon alfa-2b in HIV-infected patients. Eur J Med Res 2006 11:27 32.
8. Trizna Z, Evans T, Bruce S et al. A randomized phase II study comparing four different interferon therapies in patients with recalcitrant condylomata acuminata. Sex Transm Dis 1998 25:361 5.
9. Syed TA, Lundin S, Cheema KM et al. Human leukocyte interferon-alpha in cream, for the treatment of genital warts in Asian women: a placebo-controlled, double-blind study. Clin Investig 1994 72:870 3.
10. Fife KH, Ferenczy A, Douglas JM Jr. et al. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. Sex Transm Dis 2001 28:226 31.
11. Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human Papilloma Virus. Arch Dermatol 1998 134:25 30.
12. Garland SM, Waddell R, Mindel A et al. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int J STD AIDS 2006 17:448 52.
13. Yan J, Chen SL, Wang HN, Wu TX. Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata. Dermatology 2006 213:218 23.
14. Sauder DN, Skinner RB, Fox TL, Owens ML. Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis 2003 30:124 8.
15. Gilson RJ, Shupack JL, Friedman-Kien AE et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS 1999 13:2397 404.
16. Garland SM, Sellors JW, Wikstrom A et al. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts - results of an open-label, multicentre Phase IIIB trial. Int J STD AIDS 2001 12:722 9.
17. Arican O, Guneri F, Bilgic K, Karaoglu A. Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol 2004 31:627 31.
18. Vexiau D, Decuypere L, Moyse D, Aractingi S. Efficacy and safety of 5% imiquimod cream in external genital warts: a 6 month follow-up evaluation. Ann Dermatol Venereol 2005 132:845 51.
19. Kaspari M, Gutzmer R, Kaspari T et al. Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma. Br J Dermatol 2002 147:757 9.
20. Hoyme UB, Hagedorn M, Schindler AE et al. Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment. Infect Dis Obstet Gynecol 2002 10:79 88.
21. Wieland U, Brockmeyer NH, Weissenborn SJ et al. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol 2006 142:1438 44.
22. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006 55:1 94.
23. Gross G. Condylomata acuminata and other HPV-associated manifestations of the genitals and urethra. Guideline of the German STD Society (DSTG). Hautarzt 2001 52:405 10.
24. von Krogh G, Lacey CJ, Gross G et al. European guideline for the management of anogenital warts. Int J STD AIDS 2001 12 (Suppl. 3 40 7.
25. FitzGerald M, Workowski K. Developing sexually transmitted disease guidelines in the USA and the UK. Int J STD AIDS 2007 18:7 10.